Erlotinib response in a NSCLC patient with a novel compound G719D+L861R mutation in EGFR

Documenti analoghi

• Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
  di: Watanabe, Satoshi, et al.
  Pubblicazione: (2014)
• EGFR Exon 19 Deletion Mutations and Systemic/CNS Miliary Metastasis: Clinical Correlations and Response to Therapy
  di: Poonia, Seerat, et al.
  Pubblicazione: (2014)
• Targeted Therapies in NSCLC: Emerging oncogene targets following the success of EGFR
  di: Berge, Eamon M, et al.
  Pubblicazione: (2013)
• Long-term Survival With Afatinib in a Patient With Lung Adenocarcinoma Harboring Double Uncommon EGFR L861Q and G719X Mutations
  di: OHARA, GEN, et al.
  Pubblicazione: (2020)
• EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
  di: Wang, Qiushi, et al.
  Pubblicazione: (2013)